RT Journal Article
SR Electronic
T1 Cerebral Venous Sinus Thrombosis Associated with SARS-CoV-2; a Multinational Case Series
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.12.20186106
DO 10.1101/2020.09.12.20186106
A1 Mowla, Ashkan
A1 Shakibajahromi, Banafsheh
A1 Shahjouei, Shima
A1 Borhani-Haghighi, Afshin
A1 Rahimian, Nasrin
A1 Baharvahdat, Humain
A1 Naderi, Soheil
A1 Khorvash, Fariborz
A1 Altafi, Davar
A1 Ebrahimzadeh, Seyed Amir
A1 Farahmand, Ghasem
A1 Far, Alaleh Vaghefi
A1 Sharma, Vijay K.
A1 Neshin, Saeideh Aghayari Sheikh
A1 Tsivgoulis, Georgios
A1 Zand, Ramin
YR 2020
UL http://medrxiv.org/content/early/2020/09/13/2020.09.12.20186106.abstract
AB Background SARS-CoV-2 induced coagulopathy can lead to thrombotic complications such as stroke. Cerebral venous sinus thrombosis (CVST) is a less common type of stroke which might be triggered by COVID-19. We present a series of CVST cases with SARS-CoV-2 infection.Methods In a multinational retrospective study, we collected all cases of CVST in SARS-CoV-2 infected patients admitted to nine tertiary stroke centers from the beginning of the pandemic to June 30th, 2020. We compared the demographics, clinical and radiological characteristics, risk factors, and outcome of these patients with a control group of non-SARS-CoV-2 infected CVST patients in the same seasonal period of the years 2012-2016 from the country where the majority of cases were recruited.Results A total of 13 patients fulfilled the inclusion criteria (62% women, mean age 50.9± 11.2 years). Six patients were discharged with good outcomes (mRS≤2) and three patients died in hospital. Compared to the control group, the SARS-CoV-2 infected patients were significantly older (50.9 versus 36.7 years, p<0.001), had a lower rate of identified CVST risk factors (23.1% versus 84.2%, p<0.001), had more frequent cortical vein involvement (38.5% versus 10.5%, p: 0.025), and a non-significant higher rate of in-hospital mortality (23.1% versus 5.3%, p: 0.073).Conclusion CVST should be considered as potential comorbidity in SARS-CoV-2 infected patients presenting with neurological symptoms. Our data suggest that compared to non-SARS-CoV-2 infected patients, CVST occurs in older patients, with lower rates of known CVST risk factors and might lead to a poorer outcome in the SARS-CoV-2 infected group.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:the Institutional Review Board (IRB) of Geisinger Health SystemAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.